August 07, 2020 - Pfizer Inc. (New York, NY) announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide … [Read more...]
Pfizer, BioNTech to supply Japan with 120 million doses of MRNA-based COVID-19 vaccine candidate
July 31, 2020 – Pfizer (New York, NY) and BioNTech SE (Germany) announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV2 (the virus that causes COVID-19), subject to clinical success and regulatory approval, beginning in 2021. Financial details of the … [Read more...]
Pfizer, BioNTech announce agreement with U.S. government for up to 600 million doses of COVID-19 vaccine candidate
July 22, 2020 – Pfizer Inc. (New York, NY) and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) to meet the U.S. government’s “Operation Warp Speed” program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S. government … [Read more...]
Pfizer, Biontech granted FDA Fast Track designation for two investigational MRNA-based vaccine candidates for SARS-COV-2
Pfizer Inc. (New York, NY) and BioNTech SE announced that two of the companies’ four investigational vaccine candidates from their mRNA-based vaccine program being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). The two vaccine candidates are currently being … [Read more...]